Pharmaceutical Technology
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
📊
AI Sentiment
Positive
7/10
- Home
- PFE
PFE
Pfizer Inc.
as of 12-10-2025 9:38am EST
$25.26
$0.11
-0.43%
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Chart Type:
Time Range:
| Founded: | 1849 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 145.4B | IPO Year: | N/A |
| Target Price: | $28.30 | AVG Volume (30 days): | 63.4M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.73 | EPS Growth: | 131.89 |
| 52 Week Low/High: | $20.91 - $27.69 | Next Earning Date: | 11-04-2025 |
| Revenue: | $62,785,000,000 | Revenue Growth: | 3.89% |
| Revenue Growth (this year): | -0.79% | Revenue Growth (next year): | -1.21% |
Latest Pfizer Inc. News
PFE Breaking Stock News: Dive into PFE Ticker-Specific Updates for Smart Investing
PR Newswire
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
📈
AI Sentiment
Highly Positive
8/10
Business Wire
Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma
📈
AI Sentiment
Highly Positive
8/10
GlobeNewswire
Strategic Pharma Collaborations Propel RCC Market Growth
📈
AI Sentiment
Highly Positive
8/10
Zacks Small Cap Research
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response
📈
AI Sentiment
Highly Positive
8/10
The Wall Street Journal
Drugmakers Are Ditching Middlemen to Sell Directly to Patients
📊
AI Sentiment
Positive
6/10
MT Newswires
Pfizer Says Hympavzi Reduced Bleeds by 93% Compared With On-Demand Treatment in Phase-3 Study
âž–
AI Sentiment
Neutral
5/10
Compare PFE vs Leading Stocks
See how PFE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PFE Pfizer Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.